ATLAS 2030
Devicesessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
NCT Number: NCT05926635
Cerebral Palsy (CP) is the first cause of motor disability in children worldwide. ATLAS 2030 is a robotic gait exoskeleton designed to rehabilitate children with motor disability. The objective of this study is to analyse the efficacy of a training program with ATLAS 2023 in chilren with CP.
This study is active but is not currently recruiting participants.
Notify Me3 year–14 year
All sexes
Observational
Hospital Infantil Universitario Niño Jesús-Servicio de Rehabilitación, Madrid, Spain
A sample of children with CP will be divided into 2 groups, the experimental group will receive 32 sesions withe the ATLAS 2030 exoskeleton, whereas the control group will continue to receive their regular conventional therapy. Assessments will be performed at the beginning and the end of the intervention, as well as after 6, 9 and 12 months of the end of the intervention for follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
sessions of rehabilitation with the ATLAS 2030 exoskeleton twice per week as part of their routine rehabilitation
Time frame: At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)
To measure changes in gross motor function in children with cerebral palsy using the Gross Motor Functional Measure-88.
The minimum value is 0 and the maximum value is 100 .When the GMFM score is lower, the skill level is lower.
Time frame: Through study completion, along 1 year
changes in spasticity measured by the Modified Ashworth Scale (MAS). The spasticity of each muscle group is measured with a scale scored from 0 to 4, where 0 means no spasticity and 4 means the joint is fixed and therefore, the highest level of spasticity
Time frame: At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)
Changes in self perceived quality of life measured by the Pediatric Quality of Life Inventory (PedsQLTM). Every item is measured on a scale from 0 (higher quality of life) to 4 (lower quality of life)
Time frame: At the beginning and the end of the intervention (4 months), as well as after 6, 9 and 12 months (follow-up)
Changes in Gait Deviation Index (GDI) measured with a tridimensional motion analysis system
MarsiBionics
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04360395
Brain Damage, Chronic, Brain Diseases
Boys Town, Nebraska, United States
View Trial DetailsNCT06586437
Brain Damage, Chronic, Brain Diseases
Boys Town, Nebraska, United States
View Trial DetailsNCT06852664
Brain Damage, Chronic, Brain Diseases
Boys Town, Nebraska, United States
View Trial DetailsNCT07651995
Brain Damage, Chronic, Brain Diseases
Faisalābad, Punjab Province, Pakistan
View Trial Details